Collectively, these results from the clinical sample analysis suggest that compared with that in endocrine‐sensitive breast cancer, the innate immune signaling sensing cytosolic DNA is downregulated in endocrine‐resistant breast cancer cells, which is associated with the prognosis of ER+HER2– breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.